Product Code: RP-ID-10086120 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086120
Market Overview:
Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) 2022-2030
"The antifungal drug market in 2021 is estimated to be ~USD 2 billion, and is expected to grow at a compound annual growth rate of 4% over the period 2022-2030. The COVID-19 pandemic is expected to have a significant impact on the market. As import and export activities are restricted due to the closure, the shortage and irregular supply of raw materials and finished medical supplies and medicines are expected to have a negative impact on the research market. However, this allows local manufacturers to increase their market share. Due to the temporary closure of production bases, export bans, increased demand for drugs to treat COVID-19, and drug storage, some countries have experienced supply disruptions and shortages of medical supplies. To deal with the disruption of the pharmaceutical supply chain. For example, the European Medicines Agency has issued guidelines on the regulatory framework for companies responsible for the production of medicines to deal with the challenges they face in this pandemic situation. These measures are designed to minimize the impact of the pandemic on production and supply. Due to the increasing incidence of the pandemic, many public and private organizations have taken the initiative and stepped forward to find a cure for the disease.
There are now new reports from 2020 that up to one-third of severely infected COVID-19 patients require intensive care and may also be fighting another life-threatening infection: invasive aspergillosis, a disease caused by Deadly fungal double infection caused by mold. Aspergillus. Therefore, researchers have found that COVID-19 patients may be at increased risk of lung infections due to inhalation of mold. Therefore, scientists are working hard to conduct more research in this area. In the second wave of COVID-19 infections in India, scientists began to diagnose patients with COVID-19 or who are recovering from mucormycosis.
In May 2021, the Comptroller General of Medicines of India (DCGI) approved applications from five pharmaceutical companies for the production of amphotericin B, an antifungal drug used to treat mucormycosis. Therefore, this pandemic is expected to increase the demand for OTC products in the short term, but the number of prescription drugs and diagnostic drugs is reduced, and the supply chain of medical supplies is interrupted, which may cause temporary setbacks in the market.
The main factors driving the growth of the antifungal drug market include increased awareness of countless fungal infections, the increase in the number of over-the-counter (OTC) antifungal drugs, and the increase in the use of antifungal drugs in developing countries. country. With the increasing popularity of over-the-counter (OTC) drugs such as clotrimazole, econazole, ketoconazole, miconazole, and amorolfine, many patients prefer to use over-the-counter drugs to obtain prescriptions from healthcare professionals.
Onychomycosis, a fungal infection of fingernails and toenails, is also expected to drive market growth. For example, according to an article published by the National Institutes of Health by Myron A. Bodman in 2020, onychomycosis is on the rise globally, and the prevalence is estimated to be between 1% and 8% of the total number of nail infections. In addition to the same source, patients are usually susceptible to autosomal dominant dermatophytes. Risk factors associated with this condition include aging, diabetes, tinea pedis, psoriasis, and immunodeficiency. In addition, according to the article high prevalence of global mixed infections of onychomycosis " published in September 2020, the global prevalence of onychomycosis is estimated to be 10%, with the highest incidence of the infectious organism Trichophyton rubrum. It is expected that during the forecast period, the increasing burden of infections such as onychomycosis will drive market growth.
REPORT SCOPE :
According to the scope of this report, antifungal drugs refer to drugs used to treat diseases caused by fungi. Antifungal drugs market by drug type (echinocandins, azoles, polyenes, allylamines and other types of drugs), indications (aspergillosis, dermatophytosis, candidiasis and other indications) , Dosage forms (powders, ointments, tablets and other dosage forms) are subdivided and geographically (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the value (in billions of dollars) of the aforementioned market segments.
MAIN MARKET TRENDS
The azole market segment is expected to become one of the main contributors to the market. Due to the development of new antifungal drugs using azoles, antifungal drug research is gaining momentum. Azoles are synthetic and semi-synthetic compounds that are widely used for superficial and invasive fungal infections. These drugs are used to treat thrush, yeast infections, yeast infections, aspergillosis, tinea versicolor, Hong Kong feet, tinea cruris, ringworm, fungal infections, systemic fungal diseases and seborrheic dermatitis.
Azole antifungals include two types of triazoles (fluconazole, itraconazole, voriconazole, posaconazole and isaconazole) and imidazoles (ketoconazole). Triazole drugs have a wide range of applications in the treatment of superficial and systemic fungal infections. Azoles provide a wide range of activities and a better level of safety. There are few adverse drug reactions, the drug interaction is not serious, and the absorption and distribution characteristics are good.
The above-mentioned advantages of azoles make it dominate in other fields. Therefore, azoles are currently the most widely used and studied antifungal agents. There are different formulations of medicines (capsules, creams, sterile intravenous injections, lotions, vaginal creams and tablets). The advancement and innovation of these potential drugs has increased the competitiveness of the pharmaceutical market. The sales of established agents and recently launched antifungal agents are large.
In addition, in 2019, Mayne Pharma announced the launch of TOLSURA (SUBA-Itraconazole) 65mg capsules in the United States. TOLSURA is an itraconazole preparation for the treatment of systemic fungal infections, including blastomycosis, histoplasmosis, aspergillosis, etc. Therefore, all these factors are expected to promote the growth of this segment during the forecast period; however, there are some previously reported problems, such as the increased resistance observed in Candida and Aspergillus species, especially against azoles It is believed that this is driven by the use of azoles in agriculture. The infection rate in many developed countries is also high, which is expected to drive market demand.
NORTH AMERICA IS EXPECTED TO OCCUPY THE LARGEST MARKET SHARE :
The United States is one of the most developed economies in the world. It currently owns most of the market. The fungal disease in the United States poses a challenge to the country's health authorities. According to the Centers for Disease Control and Prevention (CDC), certain types of Candida, the most common cause of healthcare-related bloodstream infections in the United States, have been noted to be resistant.
About 7% of all Candida bloodstream isolates tested by CDC are resistant to fluconazole. In the past two decades, this observation has remained fairly stable. However, resistance to echinocandin has been increasing. In addition, the incidence of multidrug resistance in the country has also increased. In addition, the aging population in the United States is increasing. According to the "Aging of the World Population in 2019; report, there were approximately 53,340 people aged 65 and over in 2019. It is estimated that this population will reach 70,842 by 2030, accounting for approximately 20% of the country's total population. This population is more susceptible to chronic diseases, such as cancer, which damage the immune system. As a result, the population will be more susceptible to fungal diseases, which will drive the countrys demand for antifungal drugs.
This population is more susceptible to chronic diseases, which damage the immune system. As a result, the population will be more susceptible to fungal diseases, which will drive the countrys demand for antifungal drugs. Although significant progress has been made in the field of antifungal therapy, the morbidity and mortality associated with fungal diseases have remained unchanged for more than a decade. The continued high prevalence of fungal diseases will provide opportunities for pharmacists in the country to develop new and more effective fungal disease drugs, thereby promoting market growth.
COMPETITIVE LANDSCAPE :
Due to the presence of some small players and other very large players, the researched market is moderately integrated. Some market participants are Abbott Laboratories, Bayer, Astellas, Glenn Mark, GlaxoSmithKline, Merck, Novartis, Pfizer, etc.
Major Players
Abbott Laboratories
Bayer AG
GlaxoSmithKline Plc
Merck & Co., Inc.
Glenmark
LATEST PROGRESS
In June 2021, Cadila Pharmaceuticals launched a new triazole antifungal drug, posaconazole, which is effective against a variety of invasive fungal diseases. In addition, the drug is recommended as a second-line treatment for mucormycosis. In June 2021, Scinexis announced that the US Food and Drug Administration approved Brexafemme for the treatment of vaginal yeast infections."
Merck & Co., Glaxo Smith Kline, Astellas Pharma, Sanofi, Abbott Laboratories, Bayer, Kramer Laboratories, Novartis International AG, Pfizer.
Related Reports
Proof of Quality & Reliability
